Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

ELMD vs DXR: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

DXR Captures Overall Composite Edge (52.2 HOLD vs 41.1 SELL), While ELMD Leads 4–2 on Growth & Valuation Pillars

DXR Overall Winner 6-Pillar Tally: ELMD 4 – 2 DXR Matrix Metrics: ELMD 4 – 5 DXR

As of Nov 16, 2026, Daxor Corporation (DXR) captures the overall head-to-head institutional edge over Electromed, Inc. (ELMD) on higher Unified Composite conviction (52.2/100 HOLD vs. 41.1/100 SELL) after splitting the core matrix 5–4 (led by Growth & Scale, Options & Positioning), while ELMD wins 4–2 across the 6-pillar growth and valuation breakdown. ELMD trades at $23.10 (15.6x Forward P/E, 19.4% operating margin) versus DXR at $8.36 (64.5x Forward P/E, -5894.3% operating margin).

  • Growth vs. Quality Trade-Off: DXR earns the overall head-to-head edge with a stronger Unified Composite Score (52.2/100 HOLD vs. ELMD 41.1/100 SELL) and 0.28β · 32% Vol risk profile, whereas ELMD leads top-line expansion (+10.6% YoY revenue growth, 0.35x PEG, and 4 of 6 institutional pillars) for higher-beta growth mandates.
  • Technical & Structure Timing Caution: ELMD is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 25.3); meanwhile DXR is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 31.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About ELMD vs DXR
ELMD NYSE American
Electromed, Inc.
Electromedical & Electrotherapeutic Apparatus
$23.10
-5.02% 1D
Market Cap $198.8M
TTM Revenue $76M
Forward P/E 15.6x
Beta / 30D Vol 0.76β · 45% Vol
Unified Composite Score
41.1 / 100 SELL
Tech 25.0 Fund 45.0 Flow 60.0 Mom 55.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -12.5%), weak momentum, RSI 25
RSI-14: 25.3 · SMA20: $26.52 · SMA50: $27.12
DXR NASDAQ Head-to-Head Winner
Daxor Corporation Common Stock
Surgical & Medical Instruments & Apparatus
$8.36
-1.47% 1D
Market Cap $49.5M
TTM Revenue $31,360
Forward P/E 64.5x
Beta / 30D Vol 0.28β · 32% Vol
Unified Composite Score
52.2 / 100 HOLD
Tech 52.0 Fund 59.0 Flow 50.0 Mom 64.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -5.2%), weak momentum, RSI 31
RSI-14: 31.2 · SMA20: $8.91 · SMA50: $10.07

6-Pillar Scorecard Institutional Category Breakdown (ELMD 4 – 2 DXR)

Columns: Metric · ELMD · DXR
1. Valuation Multiples ELMD
Forward P/E 15.6x 64.5x
Trailing P/E 17.6x 7.7x
PEG Ratio 0.35x N/M
EV / Revenue 2.6x N/M
2. Growth & Scale DXR
Revenue Growth (YoY) +10.6% +25.5%
Earnings Growth (YoY) +28.0% +329.3%
TTM Revenue (USD) $76M $31,360
Market Cap $198.8M $49.5M
3. Profitability & Quality ELMD
Gross Margin 79.0% 100.0%
Operating Margin 19.4% -5894.3%
Net Profit Margin 15.8% 19861.4%
Return on Equity (ROE) 24.5% 14.2%
4. Balance Sheet & Cash Flow ELMD
Cash Generation (TTM) $8.6M N/A
Cash Flow Margin 11.4% N/A
Net Cash / Leverage $6.37 Book/Sh · 24.5% ROE $8.88 Book/Sh · 14.2% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning DXR
Options Structure Phase BREAKDOWN UNCLASSIFIED
Current IV / %ile 43.0% (11th %ile) N/A (N/A)
Put/Call OI Skew 0.23x (Call-Skewed) N/A
OBV Trend / Tech Phase DISTRIBUTION · Markdown NEUTRAL · Markdown
6. R&D & Supply-Chain Moat ELMD
OpEx & R&D Intensity 59.6% of Rev ($45M) N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Scale & Operating Efficiency Moat Cyclical / Execution-Driven Positioning
Supply-Chain Role Medical Devices Operator Medical Instruments & Supplies Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: ELMD (4) vs DXR (5)
Institutional Metric ELMD DXR Criterion Row Edge
Market Capitalization
Scale
$198.8M $49.5M Larger Scale ELMD
Trailing P/E Ratio
Valuation
17.6x 7.7x Lower Multiple DXR
Forward P/E Ratio
Valuation
15.6x 64.5x Lower Multiple ELMD
Revenue Growth (YoY)
Growth
+10.6% +25.5% Higher Growth DXR
Operating Margin (TTM)
Profitability
19.4% -5894.3% Higher Margin ELMD
Net Profit Margin
Profitability
15.8% 19861.4% Higher Margin DXR
Return on Equity (ROE)
Capital Efficiency
24.5% 14.2% Higher ROE ELMD
52-Week Range Position
Momentum
2% ($23–$47) 2% ($8–$15) Stronger Trend Tie
Beta / 30D Volatility
Risk Regime
0.76β · 45% Vol 0.28β · 32% Vol Lower Realized Risk DXR
Unified Institutional Score
Composite Signal
41.1 / 100 (SELL) 52.2 / 100 (HOLD) Higher Composite DXR
Trailing 12M Revenue (USD)
Operating Scale
$76M $31,360 FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
79.0% 100.0% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
0.35x PEG · 2.6x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$8.6M ($6.37 Book/Sh · 24.5% ROE) N/A ($8.88 Book/Sh · 14.2% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon ELMD +1.12 pp
ELMD: -15.75% · DXR: -16.87%
3M Horizon DXR +26.04 pp
ELMD: -45.7% · DXR: -19.66%
6M Horizon ELMD +7.82 pp
ELMD: -9.62% · DXR: -17.44%
1Y Horizon ELMD +20.94 pp
ELMD: -12.33% · DXR: -33.27%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ELMD vs DXR. Trailing 12-month operating profitability (ELMD 19.4% vs DXR -5894.3%) and valuation multiples (ELMD 15.6x vs DXR 64.5x Forward P/E) are benchmarked directly in Pillar 4 below.

ELMD ADR TTM Benchmark FX-Normalized USD
TTM Revenue$76M
Gross Margin79.0%
Op. Margin19.4%
ROE / Fwd P/E24.5% · 15.6x
DXR ADR TTM Benchmark FX-Normalized USD
TTM Revenue$31,360
Gross Margin100.0%
Op. Margin-5894.3%
ROE / Fwd P/E14.2% · 64.5x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
ELMD BREAKDOWN
94d in phase · OBV DISTRIBUTION
Current IV 43.0%
IV Percentile 11th %ile
Put/Call OI Skew 0.23x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BEARISH
OBV Flow DISTRIBUTION
Exact ELMD Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
DXR UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact DXR Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
ELMD Moat Profile Scale & Operating Efficiency Moat
Medical Devices Operator
Competes within the Medical Devices value chain with $198.8M market capitalization and 19.4% operating margin.
OpEx & R&D Reinvestment 59.6% of Rev ($45M)
90D Engineering Disclosures 0 Published
DXR Moat Profile Cyclical / Execution-Driven Positioning
Medical Instruments & Supplies Operator
Competes within the Medical Instruments & Supplies value chain with $49.5M market capitalization and -5894.3% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ ELMD vs DXR Key Questions & Quantitative Answers

As of Nov 16, 2026, Daxor Corporation (DXR) captures the overall head-to-head institutional edge over Electromed, Inc. (ELMD) on higher Unified Composite conviction (52.2/100 HOLD vs. 41.1/100 SELL) after splitting the core matrix 5–4 (led by Growth & Scale, Options & Positioning), while ELMD wins 4–2 across the 6-pillar growth and valuation breakdown. ELMD trades at $23.10 (15.6x Forward P/E, 19.4% operating margin) versus DXR at $8.36 (64.5x Forward P/E, -5894.3% operating margin). Growth vs. Quality Trade-Off: DXR earns the overall head-to-head edge with a stronger Unified Composite Score (52.2/100 HOLD vs. ELMD 41.1/100 SELL) and 0.28β · 32% Vol risk profile, whereas ELMD leads top-line expansion (+10.6% YoY revenue growth, 0.35x PEG, and 4 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: ELMD is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 25.3); meanwhile DXR is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 31.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

DXR leads the Growth & Scale pillar: ELMD posts +10.6% YoY revenue growth and +28.0% YoY earnings growth on $76M TTM revenue (79.0% gross margin, 19.4% operating margin), compared with DXR at +25.5% YoY revenue growth and +329.3% YoY earnings growth on $31,360 TTM revenue (100.0% gross margin, -5894.3% operating margin). On trailing 12-month operating scale, ELMD generates $76M in USD-normalized revenue versus $31,360 for DXR. In operating R&D and SG&A reinvestment, ELMD deploys 59.6% of Rev ($45M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for DXR.

ELMD screens cheaper on headline valuation multiples. ELMD trades at 15.6x Forward P/E, 17.6x Trailing P/E, 0.35x PEG, and 2.6x EV/Revenue (11.4% FCF margin), whereas DXR trades at 64.5x Forward P/E, 7.7x Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ELMD (24.5% ROE) versus DXR (14.2% ROE) capital efficiency.

In options market volatility and institutional positioning, ELMD carries 43.0% implied volatility (11th %ile, Compressed (<25th %ile)), a 0.23x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (0.76β · 45% Vol realized risk). By comparison, DXR carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.28β · 32% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.